Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 19 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced an exclusive licensing and supply agreement with Synthon for Palbociclib Tablets, a generic version of IBRANCE, intended for the US market. Under this agreement, Synthon will handle regulatory approval and manufacturing, while Zydus will focus on commercialization. This partnership aims to address significant unmet medical needs in oncology for patients in the US.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 19, 2024, titled "Zydus and Synthonenter into an exclusive licensing and supply agreement for Palbociclib Tablets (genericversion of IBRANCE��) for the US market".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases